Physician profile
Britney Pridgen
NPI 1245839570
$57,080.46
in general payments reported to CMS, 2019-2025
12 companies · $6,911 in 2025
The $6,911 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,307 · 2022: $21K · 2023: $16K · 2024: $7,959 · 2025: $6,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $5,141 · Food and Beverage: $3,691 · Travel and Lodging: $2,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,981.40 |
| Consulting Fee | $5,141.00 |
| Food and Beverage | $3,691.42 |
| Travel and Lodging | $2,525.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $27,385.00 | 2021-2025 | Abilify Mycite, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $22,765.93 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $5,919.76 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $304.84 | 2021-2025 | Rejoyn |
| Teva Pharmaceuticals USA, INC. | $231.81 | 2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $184.06 | 2022-2024 | Invega Sustenna, Invega |
| Tris Pharma INC | $124.02 | 2023 | Quillichew Er, Dyanavel Xr, Quillivant |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.00 | 2023-2025 | Caplyta |
| Corium, LLC | $30.62 | 2022 | |
| Luye Pharma (USA) Ltd. | $19.62 | 2025 | Erzofri Extended-Release |
| Axsome Therapeutics, INC. | $19.30 | 2025 | Auvelity |
| Indivior INC. | $13.50 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britney Pridgen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.